Baird raised the firm’s price target on Denali Therapeutics (DNLI) to $32 from $29 and keeps an Outperform rating on the shares. The firm updated its model as the Avlayah approval christens its transition to a commercial stage company.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNLI:
- Denali Therapeutics: Avlayah Launch and Platform De-Risking Support Commercial Upside and Higher Valuation
- Denali Therapeutics Gains FDA Approval for AVLAYAH Therapy
- Denali Therapeutics granted FDA approval of AVLAYAH for treatment of MPS II
- Denali Therapeutics price target raised to $36 from $32 at BTIG
- Denali Therapeutics price target lowered to $34 from $37 at Stifel